Sanofi has returned to T-cell engager (TCE) territory via an agreement to pay $180 million in the near term for a phase ...

Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, will present new data at the American ...

Data are beginning to provide a clearer picture of chimeric antigen receptor T-cell therapy’s benefits and risks in lupus, ...

Chimeric antigen receptor T-cell therapy—CAR T for short—has been a major advance in treating blood cancers like leukemia and ...

Renier Brentjens, MD, PhD, one of the pioneers in the development of chimeric antigen receptor (CAR) T-cell therapy, is poised to see the technology take its next big leap, with researchers testing ...

A new CAR T-cell therapy attacks supportive cells in the tumor microenvironment that bear the surface protein, uPAR.

Kali Therapeutics, a biotechnology company focused on the discovery and development of next-generation biologics, today announced that they have entered into a license agreement with Sanofi for a ...

T cell activation—the process by which these key immune defenders recognize threats and mobilize against them—depends on exquisitely timed molecular signals. Now researchers have captured one of the ...

CAR T-cell therapy shows promise for SCLC, but significant barriers, such as tumor heterogeneity and immunosuppression, must be addressed. Identifying tumor-selective antigens like CDH17, GD2, and ...